Z. Cuthbertson

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.

C. Brander, V. Miller, T. Peto, 2021, Cell reports.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

M. Johnson, V. Miller, T. Peto, 2020, The Lancet.

Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.

M. Youle, H. Wand, M. Law, 2008, The Journal of antimicrobial chemotherapy.

Intracellular and Plasma Pharmacokinetics of Nelfinavir and M8 in HIV-Infected Patients: Relationship with P-Glycoprotein Expression

D. Cornforth, M. Johnson, S. Khoo, 2004, Antiviral therapy.

Resolution of azole-resistant oesophageal candidiasis in an AIDS patient after treatment with caspofungin.

M. Youle, M. Johnson, Z. Cuthbertson, 2003, AIDS.

Incoming HIV Virion-Derived Gag Spacer Peptide 2 (p1) is a Target of Effective CD8+ T Cell Antiviral Responses

C. Brander, V. Miller, T. Peto, 2020, SSRN Electronic Journal.

Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?

A. Phillips, F. Lampe, M. Youle, 2002, AIDS.